Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 36,46 € (+2,79 %). Medianen er 36,46 € (+2,79 %).
| Køb |
8 |
| Behold |
6 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Centessa announces CEO change; shares fall after strategic realignment
Centessa reports that Mario Alberto Accardi will replace Saurabh Saha as CEO on January 1, 2026, and join the board; Saha is stepping down and will remain as an adviser. The stock subsequently fell about 4%. The company is refocusing its strategy on the orexin/OX2R portfolio: lead candidate ORX750 is expected to enter an approval-relevant program for narcolepsy and idiopathic hypersomnia in the first quarter of 2026, and other OX2R candidates such as ORX142 and ORX489 are expected to hit key milestones in 2026. » Mere på de.investing.com
Centessa Pharmaceuticals hits 52-week high at $25.44
The ADRs of Centessa Pharmaceuticals rose to a 52-week high of $25.44 after the stock gained 32.59% over the past year and 71.41% in six months; the current price is about 166% above the annual low of $9.60. Analyst price targets range from $27 to $49, while InvestingPro flags a possible overvaluation versus fair value. Centessa announced a public offering of 11.6 million ADS at $21.50 (gross proceeds ~ $250 million, fully underwritten) and received a buy from Truist with a $30.00 target following preliminary phase-2a data on ORX750. » Mere på de.investing.com
Centessa announces public offering of ADS, shares fall in after-hours
Centessa's share fell about 2.5% in after-hours trading after the company announced a guaranteed public placement of American Depositary Shares (each representing one common share). All offered ADS will be sold by Centessa, and the underwriting banks have a 30-day option to purchase up to 15% of the shares. Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint bookrunners; the offering is subject to market and other conditions and may lead to dilution for existing shareholders. » Mere på de.investing.com
Centessa Pharmaceuticals sets ADS offering price at $21.50
Centessa Pharmaceuticals sets the price for a public, syndicated offering of 11,627,907 American Depositary Shares (ADS) at $21.50 per ADS and expects gross proceeds of about $250 million before expenses. The transaction, in which all of Centessa’s ADSs will be sold, is expected to close around November 14, 2025, and includes a 30-day overallotment option for up to 1,744,186 ADS. Joint book-running managers are Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities; the ADSs are being offered on the basis of a Form S-3 filed in September 2024. » Mere på de.investing.com
Centessa Pharmaceuticals hits 52-week high at $25.35
Centessa Pharmaceuticals ADRs marked a new 52-week high at $25.35 and are up about 56.7% year to date. Market capitalization is roughly $3.34 billion; analyst price targets range from $27 to $40, with Stephens, Oppenheimer and Truist recently issuing buy recommendations or positive ratings. Key upcoming events include the quarterly report on November 17 and expected Phase‑2a data for ORX750 before year‑end. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | marts 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | -206,13 t | - |
| Nettoresultat | -68,46 mio. | - |
| EBITDA | -65,16 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 5,71 mia. € |
Antal aktier | 154,73 mio. |
Højeste/laveste i 52 uger | 36,97 € - 11,65 € |
Udbytteafkast | 94,36 % |
Udbytte TTM | 33,47 € |
Beta | 1,12 |
P/E (PE Ratio) | -22,75 |
PEG (PEG Ratio) | 3,15 |
K/I (PB Ratio) | 12,76 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Centessa Pharmaceuticals plc er et lægemiddelselskab i klinisk fase, der opdager, udvikler og leverer lægemidler til patienter. Selskabets registreringsnære pipeline omfatter Lixivaptan, en vasopressin V2-receptor-small molecule-hæmmer, der er i fase III klinisk udvikling til behandling af autosomal dominant polycystisk nyresygdom; og SerpinPC, en hæmmer af aktiveret protein C, som er i fase IIa klinisk udvikling til behandling af hæmofili A og B. Selskabet har også nye pipeline-produkter i klinisk proof of concept-fase, herunder LB101, en PD-L1xCD47 LockBody, samt LB201, en PD-L1xCD3 LockBody, som er designet til selektivt at fremkalde kraftig CD47- og CD3-effektorfunktion, samtidig med at systemisk toksicitet undgås; ZF874, en lille molekylær farmakologisk chaperone-foldningskorrektor af Z-varianten af alfa-1-antitrypsin, der er i fase I klinisk udvikling til behandling af alfa-1-antitrypsinmangel; MGX292, et rekombinant modificeret BMP9-erstatningsprotein designet til at overvinde manglen på BMP9-signalering ved pulmonal arteriel hypertension; og OX2R-agonister, som er orale og intranasale selektive orexin-receptor 2-agonister designet til at udnytte strukturelle indsigter og direkte adressere den underliggende patofysiologi med tab af orexinneuroner ved narkolepsi type 1. Derudover har selskabet eksplorative pipeline-produkter i klinisk proof of concept-fase, som indeholder CBS001, et anti-LIGHT-antistof, der fortrinsvis binder den inflammatoriske membranform af LIGHT ved inflammatoriske/fibrotiske sygdomme; og CBS004, et humaniseret mAb specifikt rettet mod BDCA2, som udtrykkes udelukkende på plasmacytoide dendritceller ved systemisk sklerose, systemisk lupus erythematosus og andre autoimmune sygdomme. Centessa Pharmaceuticals plc blev stiftet i 2020 og har hjemsted i Altrincham, Storbritannien.
| Navn | Centessa Pharmaceuticals ADR Aktie |
| CEO | Mario Alberto Accardi |
| Hjemsted | Altrincham,
Storbritannien |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 28.05.2021 |
| Medarbejdere | 129 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | CNTA |
Frankfurt | 260.F |
Düsseldorf | 260.DU |
München | 260.MU |
London | 0ACX.L |